Objective: To evaluate the efficacy of Donepezil in the treatment of Alzhelmer’s disease (AD) with behavioral and psychological symptoms. Methods: Forty-six AD patients with behavioral and psychological symptoms were randomly divided into two groups: observation group (Donepezil 5 mg q.n.) and control group (piracetam 800 mg t.i.d.). The efficacy was assessed by MMSE, BPRS, and ADL at baseline and 1 and 3 months after the treatment. Adverse events were recorded. Results: There was no significant difference in MMSE between the two groups at baseline (P>0.05). After the treatment of Donepezil for 3 months, significant improvement of cognition of AD patients were observed when comparing with that at baseline or of controls (P<0.05). Meanwhile, significant decline of BPRS was also revealed in observation group (P<0.05). Although no significant difference in BPRS was revealed between the two groups, there were significant alleviations revealed in observation group in 1 and 3 months than those in controls (P<0.05). No significant change of ADL score was revealed no matter between the 2 groups or before and after the treatment. Conclusion: Donepezil effectively improves the cognitive function and ability of daily life, and alleviates behavioral and psychological symptoms in AD patients.
